Estimation of Serum-Free 50-Percent Inhibitory Concentrations for Human Immunodeficiency Virus Protease Inhibitors Lopinavir and Ritonavir
Open Access
- 1 August 2004
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (8) , 2911-2917
- https://doi.org/10.1128/aac.48.8.2911-2917.2004
Abstract
Using measured free fraction and 50% inhibitory concentration (IC 50 ) values for the human immunodeficiency virus protease inhibitors lopinavir (LPV) and ritonavir (RTV) in tissue culture media with various protein concentrations ranging from 5 to 50%, we estimated serum-free IC 50 values for each drug. The range of serum-free IC 50 values (0.64 to 0.77 ng/ml for LPV and 3.0 to 5.0 ng/ml for RTV) did not exhibit a trend with increasing protein concentrations, despite a 10-fold difference in the free fraction value (0.006 to 0.063) for LPV and a 5-fold difference in the free fraction value (0.013 to 0.057) for RTV. The mean serum-free IC 50 by the MTT-MT4 assay (0.69 ng/ml for LPV and 4.0 ng/ml for RTV) may be the most accurate parameter for the estimation of the inhibitory quotient (IQ), a relative measure of in vivo potency defined as the ratio of the minimal free drug concentration in plasma ( C trough,free ) for a specific patient population and the serum-free IC 50 . Using this approach, we calculated the average IQs for protease inhibitor-naïve patients for LPV and RTV to be 67 and 5.6, respectively.Keywords
This publication has 34 references indexed in Scilit:
- Pharmacokinetic-Pharmacodynamic Analysis of Lopinavir-Ritonavir in Combination with Efavirenz and Two Nucleoside Reverse Transcriptase Inhibitors in Extensively Pretreated Human Immunodeficiency Virus-Infected PatientsAntimicrobial Agents and Chemotherapy, 2003
- Virtual Inhibitory Quotient Predicts Response to Ritonavir Boosting of Indinavir-Based Therapy in Human Immunodeficiency Virus-Infected Patients with Ongoing ViremiaAntimicrobial Agents and Chemotherapy, 2002
- The relationship between ritonavir plasma trough concentration and virological and immunological response in HIV‐infected childrenHIV Medicine, 2002
- Drug Resistance and Predicted Virologic Responses to Human Immunodeficiency Virus Type 1 Protease Inhibitor TherapyThe Journal of Infectious Diseases, 2000
- In Vitro Effect of α1‐Acid Glycoprotein on the Anti‐Human Immunodeficiency Virus (HIV) Activity of the Protease Inhibitor CGP 61755: A Comparative Study with Other Relevant HIV Protease InhibitorsThe Journal of Infectious Diseases, 1997
- Relevance of Plasma Protein Binding to Antiviral Activity and Clinical Efficacy of Inhibitors of Human Immunodeficiency Virus ProteaseThe Journal of Infectious Diseases, 1996
- Changes in the Serum Protein Binding of Vancomycin in Patients with Methicillin-Resistant Staphylococcus aureus InfectionTherapeutic Drug Monitoring, 1995
- Reduction Of The In Vitro Activity Of A77003, An Inhibitor Of Human Immunodeficiency Virus Protease, By Human Serum 1 Acid GlycoproteinThe Journal of Infectious Diseases, 1995
- Novel Fluorogenic Substrates for Assaying Retroviral Proteases by Resonance Energy TransferScience, 1990
- The inhibitory quotient. A method for interpreting minimum inhibitory concentration dataJAMA, 1981